Shanghai Fosun Pharmaceutical (02196): HENLIUS (02696) will retain its H-share listing status and will continue to support its long-term healthy development as always.

On January 22, 2025, Shanghai Fosun Pharmaceutical (600196.SH; 02196) announced that the special resolution regarding the absorption merger and privatization of HENLIUS (02696) was not reached, and the absorption merger will not be implemented. HENLIUS will retain its H-share listing status. Shanghai Fosun Pharmaceutical expresses gratitude to shareholders and the community for their attention, regrets that the privatization proposal of HENLIUS did not pass, and fully respects the decision of all shareholders. Shanghai Fosun Pharmaceutical will continue to support the long-term healthy development of HENLIUS. The biopharmaceutical industry is full of challenges, and HENLIUS is an international innovative biopharmaceutical company that achieved profitability for the first time in 2023, becoming the first Hong Kong-listed 18A innovative drug company to achieve profitability through product sales. By retaining its H-share listing status, HENLIUS demonstrates the confidence of investors in HENLIUS and the future prospects of the biopharmaceutical industry. We believe that the Chinese and global biopharmaceutical markets are full of opportunities. Shanghai Fosun Pharmaceutical is committed to innovation and focuses on unmet clinical needs, strengthening core technology platforms such as antibodies/ADC, cell therapy, and small molecules. We will continue to support HENLIUS as an important antibody technology platform to deepen innovation research and development in the biopharmaceutical field, expand domestic and foreign markets, enhance global competitiveness, and achieve high-quality development. Additionally, we will increase the investment in innovative research and development in the field of large molecule drugs, promote more innovative drugs to enter the global market, improve our position in the global biopharmaceutical field, create more affordable and trustworthy biopharmaceutical products, and create value for shareholders and society.